Abstract
Crohn’s disease is a systemic, autoimmune disease affected whole the gastrointestinal system. hastalığı tüm gastrointestinal sistemi tutan sistemik otoimmun bir hastalıktır. Drug-associated autoimmune diseases such as lupus-like syndrome are going to be seen related to antiTNF-alpha that is used frequently. This case is the Crohn’s disease that acut pancreatitis has developed after the usage of azathioprine, and then adalimumab has been started, lupus-like syndrome related to adalimumab has emerged. A little part of these side effects are related to autoimmunity. This autoimmunity is associated with the increase of Th2 cytokine response, and as a result, the production of autoantibody. Drug-associated lupus is the situation that is reversible after the stopping causative agent. It must be keep in mind that drug-associated lupus-like syndrome can emerge in the patients used antiTNF-alpha.
Keywords
References
- 1. Şentürk E, Özsu S, Çapkın E, Türkyilmaz A. Lupus-like syndrome in patients treated with anti-TNF-α factors. Tuberk Toraks. 2018 Mar; 66: 72-5.
- 2. Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005 Mar; 64: 403-7.
- 3. Beigel F, Schnitzler F, Paul Laubender R, et al. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease. Inflamm Bowel Dis 2011 Jan; 17: 91-8.
Abstract
Crohn hastalığı tüm gastrointestinal sistemi tutan sistemik otoimmun bir hastalıktır. Sıklıkla kullanılan antiTNF-alfa’ya bağlı ilaç ilişkili lupus gibi otoimmun hastalıklar gözlenmektedir. Vakamız, azathioprin ile akut pankreatit gelişen ve sonrasında adalimumab’a geçilen, adalimumab kullanımı sonrası lupus benzeri sendrom gelişen Crohn hastasıdır. Bu yan etkilerin bir kısmı otoimmunite ile ilgili olup Th2 sitokin yanıtının artışı ve sonucunda otoantikor üretimi ile ilişkilidir. İlaç ilişkili lupus, suçlu ilacın kesilmesiyle klinik bulguların geri dönebildiği bir durumdur. antiTNF-alfa kullanan hastalarda gelişebileceği akılda tutulmalıdır.
References
- 1. Şentürk E, Özsu S, Çapkın E, Türkyilmaz A. Lupus-like syndrome in patients treated with anti-TNF-α factors. Tuberk Toraks. 2018 Mar; 66: 72-5.
- 2. Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis. 2005 Mar; 64: 403-7.
- 3. Beigel F, Schnitzler F, Paul Laubender R, et al. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease. Inflamm Bowel Dis 2011 Jan; 17: 91-8.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Case Report |
| Authors | |
| Publication Date | September 23, 2020 |
| Published in Issue | Year 2020 Volume: 2 Issue: 4 |
Cite
Interuniversity Board (UAK) Equivalency: 1b [Original research article published in journals scanned by international field indexes (included in indices other than the ones mentioned in 1a) - 10 POINTS].
The Directories (indexes) and Platforms we are included in are at the bottom of the page.
| |
|
Journal is indexed in;
Crossref (DOI), Google Scholar, EuroPub, Directory of Research Journal İndexing (DRJI), Worldcat (OCLC), General Impact Factor, OpenAIRE, ASOS Index, ROAD, Turkiye Citation Index, Turk Medline.
Ulakbim-TR Dizin, Index Copernicus, EBSCO, DOAJ is under evaluation.
Journal articles are evaluated as "Double-Blind Peer Review"
.
There is no charge for sending articles, submitting, evaluating and publishing.
Assoc Prof Dr Muhammed KIZILGÜL was qualified as an Associated Editor in ACMJ on 15/02/2020,
Assoc. Prof. Dr. Ercan YUVANÇ leaved, Assoc. Prof. Dr. Alpaslan TANOĞLU became the Editör in Chief in ACMJ on 13/05/2020.